GSK and CureVac to develop next generation mRNA COVID-19 vaccines. Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval. GSK will also support manufacture of up to 100 million doses of CureVac's first generation COVID-19 vaccine CVnCoV in 2021….